Skip to content

Telemedicine Self-examination of Speech and Memory for Rapid Detection of Cognitive Impairments Using Machine Learning Methods

Telemedicine Self-examination of Speech and Memory for Rapid Detection of Cognitive Impairments Using Machine Learning Methods

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07558785
Enrollment
500
Registered
2026-04-30
Start date
2023-09-01
Completion date
2026-08-31
Last updated
2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment (MCI), Dementia, Mild Cognitive Impairment (MCI) Amnestic, Frontotemporal Degeneration (FTD), Alzheimer Disease (AD)

Keywords

digital diagnostics, cognition, Mild Cognitive Impairment (MCI), dementia, screening

Brief summary

Early cognitive disorders diagnosis is becoming increasingly important due to population aging. The most common causes include Alzheimer's disease and frontotemporal dementia. These diseases are also manifested by changes in speech. NLP allows us to identify and classify these changes. The project aims to develop a web application for self-assessment and automated detection of cognitive disorders from speech. The application will have a form of a dialogue system using machine learning methods. The novelty of this approach is the possibility of an efficient self-assessment of a wide spectrum of the Czech population from their homes and an automated evaluation of test results. Early detection can be followed by a more detailed diagnosis and adequate treatment.

Interventions

DIAGNOSTIC_TESTThe Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

A brief individually administered battery to measure cognitive decline or improvement across five domains in ages 12 to 89 years 11 months.

DIAGNOSTIC_TESTthe Mississippi Aphasia Screening Test

he Mississippi Aphasia Screening Test (MAST) was developed as a brief, repeatable screening measure for individuals with severely impaired communication/language skills.

DIAGNOSTIC_TESTAmnesia Light and Brief Assessment (ALBA)

Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).

DIAGNOSTIC_TESTThe Picture naming and immediate recall test (PICNIR)

Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).

The Geriatric Depression Scale (GDS-15), used to screen for depression in adults aged 55 and older, consists of 15 items that assess mental health based on feelings over the past week.

A formative assessment and rating scale of anxiety.

DIAGNOSTIC_TESTDigitial Diagnostics of Dementia (DDD)

Our experimental screening battery developed for this study.

Sponsors

Faculty Hospital Kralovske Vinohrady
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

for the group of healthy participants: * age over 45 years * Czech as the native language * must meet the criteria in a questionnaire with questions focused on a history of brain injury or psychiatric history or medication use * must achieve normal scores on questionnaires assessing mood Inclusion Criteria for the group of patients: \- be diagnosed with mild neurocognitive impairment (MCI) or neurocognitive disorder (dementia) according to the international DSM-5 criteria

Design outcomes

Primary

MeasureTime frame
The difference in results between groups of patients with cognitive impairment and healthy individuals in individual parts of our experimental neuropsychological battery Diagnostic Test: Digitial Diagnostics of Dementia (DDD)Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with RBANSThrough study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with MASTThrough study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with ALBAThrough study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with POBAVThrough study completion, an average of 2 years

Countries

Czechia

Contacts

STUDY_CHAIRLuboš Šmídl, Ing. Ph.D.

Západočeská univerzita v Plzni / Fakulta aplikovaných věd

PRINCIPAL_INVESTIGATORJan Švec, Ing. Ph.D.

Západočeská univerzita v Plzni / Fakulta aplikovaných věd

PRINCIPAL_INVESTIGATORFilip Polák, Ing.

Západočeská univerzita v Plzni / Fakulta aplikovaných věd

STUDY_DIRECTORAleš Bartoš, prof. MUDr. Ph.D.

Fakultní nemocnice Královské Vinohrady

STUDY_DIRECTORMartin Víta, Mgr. Ph.D.

Fyzikální ústav AV ČR, v. v. i.

PRINCIPAL_INVESTIGATORMarie Kompasová, Mgr.

Univerzita Karlova, Fakultní nemocnice Královské Vinohrady

PRINCIPAL_INVESTIGATORMichaela Zapletalová, Mgr.

Univerzita Palackého, Fakultní nemocnice Královské Vinohrady

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026